Dexcom ( (DXCM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
DexCom’s stock took a hit after the FDA issued a warning letter about deficiencies in response letters related to inspections at its San Diego and Mesa facilities. The concerns were about manufacturing processes and quality management systems, but they didn’t reveal any new issues beyond previous inspections. Despite the stock drop, DexCom’s operations and product distribution remain unaffected, and the company is already working on corrective actions. Analysts remain optimistic about DexCom’s future due to its strong market position and growth potential, with no changes to its 2025 revenue guidance or production capabilities.
More about Dexcom
YTD Price Performance: -0.84%
Average Trading Volume: 3,588,780
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.07B
For further insights into DXCM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.